The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium‐glucose cotransporter 2 inhibitors such as ertugliflozin depends on glucose filtration through the kidney. This...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Pharmacol
Hauptverfasser: Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Special Populations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655776/
https://ncbi.nlm.nih.gov/pubmed/28703316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.955
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge